Significance of eosinophil cationic proteins during immunotherapy with interleukin-2 in renal cancer

F. Tacconi, E. Mainardi, M. Deamici, C. Bianchessi, E. Bobbio Pallavicini

Research output: Contribution to journalArticle

Abstract

Eosinophil cationic proteins are able to damage tissues and cells and contribute to the development of cardiovascular lesion in patients with hypereosinophilic syndrome. Eighteen patients with renal cell carcinoma treated with subcutaneous injection of interleukin-2 and interferon-α developed marked secondary eosinophilia (mean value: pretreatment 448 x 10.3/μl; posttreatment 1933 x 10.3/μl). The state of activation and granule protein release from eosinophil granulocytes were analyzed (in serum and cultures) to evaluate their role in cancer patients and to determine whether a correlation with immunological response exists. Patients were subsequently classified as responders (complete, partial or stable), nonresponders (progression of disease), or as adjuvants to this therapy. Statistically significant high eosinophil cationic protein (p

Original languageEnglish
Pages (from-to)13-17
Number of pages5
JournalInternational Journal of Immunotherapy
Volume16
Issue number1-2
Publication statusPublished - 2000

    Fingerprint

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this